Baird Maintains Outperform on Apellis Pharmaceuticals, Maintains $100 Price Target
Baird Maintains Outperform on Apellis Pharmaceuticals, Maintains $100 Price Target
Baird維持對apellis pharmaceuticals的跑贏大盤評級，維持100美元的目標價。
Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and maintains $100 price target.
Baird分析師Colleen Kusy維持Apellis Pharmaceuticals (納斯達克:APLS)爲超越業績，目標價100美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。